相似文献
1
Predetermination by infection and by vaccination of antibody response to influenza virus vaccines.
J Exp Med. 1957 Dec 1;106(6):835-50. doi: 10.1084/jem.106.6.835.
2
ANTIBODY responses and clinical reactions with saline and oil adjuvant influenza virus vaccines.
Br Med J. 1955 Nov 19;2(4950):1229-32.
3
A serologic recapitulation of past experiences with influenza A; antibody response to monovalent vaccine.
J Exp Med. 1956 Jul 1;104(1):85-97. doi: 10.1084/jem.104.1.85.
4
Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.
5
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560.
6
Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.
Immunology. 2016 Jun;148(2):160-73. doi: 10.1111/imm.12594. Epub 2016 Mar 30.
7
From Original Antigenic Sin to the Universal Influenza Virus Vaccine.
Trends Immunol. 2018 Jan;39(1):70-79. doi: 10.1016/j.it.2017.08.003. Epub 2017 Aug 31.
8
Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus.
J Exp Med. 1953 Dec;98(6):641-56. doi: 10.1084/jem.98.6.641.
9
10
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
JAMA. 2014 Oct 8;312(14):1420-8. doi: 10.1001/jama.2014.12609.
引用本文的文献
1
Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history.
Microbiol Spectr. 2025 Jul 17:e0290724. doi: 10.1128/spectrum.02907-24.
2
BA.1 breakthrough infection elicits distinct antibody and memory B cell responses in vaccinated-only versus hybrid immunity individuals.
iScience. 2025 Feb 5;28(4):111962. doi: 10.1016/j.isci.2025.111962. eCollection 2025 Apr 18.
3
A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.
J Virol. 2025 Apr 15;99(4):e0199024. doi: 10.1128/jvi.01990-24. Epub 2025 Mar 21.
4
Measures of Population Immunity Can Predict the Dominant Clade of Influenza A (H3N2) in the 2017-2018 Season and Reveal Age-Associated Differences in Susceptibility and Antibody-Binding Specificity.
Influenza Other Respir Viruses. 2024 Nov;18(11):e70033. doi: 10.1111/irv.70033.
5
Vaccination against rapidly evolving pathogens and the entanglements of memory.
Nat Immunol. 2024 Nov;25(11):2015-2023. doi: 10.1038/s41590-024-01970-2. Epub 2024 Oct 9.
6
A speed limit on serial strain replacement from original antigenic sin.
Proc Natl Acad Sci U S A. 2024 Jun 18;121(25):e2400202121. doi: 10.1073/pnas.2400202121. Epub 2024 Jun 10.
7
Cellular and Molecular Immunity to Influenza Viruses and Vaccines.
Vaccines (Basel). 2024 Apr 7;12(4):389. doi: 10.3390/vaccines12040389.
8
A polyvalent RNA vaccine reduces the immune imprinting phenotype in mice and induces neutralizing antibodies against omicron SARS-CoV-2.
Heliyon. 2024 Feb 6;10(4):e25539. doi: 10.1016/j.heliyon.2024.e25539. eCollection 2024 Feb 29.
9
A speed limit on serial strain replacement from original antigenic sin.
bioRxiv. 2024 Apr 20:2024.01.04.574172. doi: 10.1101/2024.01.04.574172.
10
Measures of population immunity can predict the dominant clade of influenza A (H3N2) in the 2017-2018 season and reveal age-associated differences in susceptibility and antibody-binding specificity.
medRxiv. 2024 Oct 10:2023.10.26.23297569. doi: 10.1101/2023.10.26.23297569.
本文引用的文献
1
The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water in-oil emulsion.
Am J Hyg. 1952 May;55(3):439-56. doi: 10.1093/oxfordjournals.aje.a119534.
2
New antigenic variant in Far East influenza epidemic, 1957.
Proc Soc Exp Biol Med. 1957 Jul;95(3):609-16. doi: 10.3181/00379727-95-23306.
3
Viruses: the versatile parasites; the arthropod-borne group of animal viruses.
Trans N Y Acad Sci. 1957 Jan;19(3):219-35. doi: 10.1111/j.2164-0947.1957.tb00526.x.
4
Influenza vaccination in a residential boys' school; report to the medical research council committee on clinical trials of influenza vaccine.
Br Med J. 1956 Nov 24;2(5003):1200-2. doi: 10.1136/bmj.2.5003.1200.
5
Prevention of acute respiratory illness in recruits by adenovirus (RI-APC-ARD) vaccine.
Proc Soc Exp Biol Med. 1956 Jun;92(2):377-83. doi: 10.3181/00379727-92-22484.
6
A serologic recapitulation of past experiences with influenza A; antibody response to monovalent vaccine.
J Exp Med. 1956 Jul 1;104(1):85-97. doi: 10.1084/jem.104.1.85.
7
Studies of antibodies to strains of influenza virus in persons of different ages in sera collected in a postepidemic period.
J Immunol. 1955 Nov;75(5):401-9.
8
A serological recapitulation of human infection with different strains of influenza virus.
Trans Assoc Am Physicians. 1953;66:231-9.
9
Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus.
J Exp Med. 1953 Dec;98(6):641-56. doi: 10.1084/jem.98.6.641.
10
The antigenic composition of influenza virus measured by antibody-absorption.
J Exp Med. 1953 Dec;98(6):619-39. doi: 10.1084/jem.98.6.619.
Zotero 插件